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Abstract
Many biopharmaceuticals (BPs) are known to be immunogenic in the clinic, which can result in
modified pharmacokinetics, reduced efficacy, allergic reactions and anaphylaxis. During recent
years, several technologies to predict immunogenicity have been introduced, but the predictive
value is still considered low. Thus, there is an unmet medical need for optimization of such
technologies. The generation of T cell dependent high affinity anti-drug antibodies plays a key
role in clinical immunogenicity. This study aimed at developing and evaluating a novel in vitro T
cell:PBMC assay for prediction of the immunogenicity potential of BPs. To this end, we asse-
ssed the ability of infliximab (anti-TNF-α), rituximab (anti-CD20), adalimumab (anti-TNF-α) and
natalizumab (anti-α4-integrin), all showing immunogenicity in the clinic, to induce a CD4+ T
cells response. Keyhole limpet hemocyanin (KLH) and cytomegalovirus pp65 protein (CMV)
were included as neo-antigen and recall antigen positive controls, respectively. By analyzing
26 healthy donors having HLA-DRB1 alleles matching the European population, we calculated
the frequency of responding donors, the magnitude of the response, and the frequency of BP-
specific T cells, as measured by 3[H]-thymidine incorporation and ELISpot IL-2 secretion. KLH
and CMV demonstrated a strong T cell response in all the donors analyzed. The frequency of
responding donors to the BPs was 4% for infliximab, 8% for adalimumab, 19% for rituximab
and 27% for natalizumab, which is compared to and discussed with their respective observed
clinical immunogenicity. This study further complements predictive immunogenicity testing by
quantifying the in vitro CD4+ T cell responses to different BPs. Even though the data generated
using this modified method does not directly translate to the clinical situation, a high sensitivity
and immunogenic potential of most BPs is demonstrated.
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Introduction
Biopharmaceuticals (BPs), such as monoclonal antibodies (mAbs) are widely used for the
treatment of autoimmune disease, and cancer. A major concern regarding treatment with
therapeutic proteins is the risk of provoking an unwanted immune response, such as the devel-
opment of anti-drug antibodies (ADAs). ADAs can potentially decrease the efficacy of the BPs,
modify clearance, induce hypersensitivity reactions or cause severe adverse events [1, 2]. Many
factors contribute to the immunogenicity of BPs, including product-, disease-, treatment- and
patient-related factors [3]. Product-related factors include intrinsic factors like homology to
human amino acids sequences and posttranslational modifications, and extrinsic factors such
as dose, formulation, route and frequency of administration, aggregates and impurities [4].
For the patient, elements like genetic factors including HLA type, gender and concomitant
medication are contributing elements [5]. Regardless of how immunogenicity is triggered, it is
evident that the formation of high affinity Abs to BPs is CD4+ T cell dependent [5, 6]. A T cell
dependent Ab response relies on T cell recognition of protein-derived epitopes that have been
taken up, processed and displayed by HLA class II on antigen presenting cells (APCs). Because
of polymorphisms in the HLA class II genes, the CD4+ T cell epitopes can differ between indi-
viduals. [7]. The importance of a potent T cell epitope has been described in several studies [8–
11]. In fact, amelioration of immunogenicity has been observed by removing T cell epitopes
from e.g. IFNβ1b [12] and mAbs [13]. Consequently, detection of BP-specific T cells in healthy
naive donors is considered as one of the major approaches to assess immunogenicity risk. Sev-
eral methods to evaluate T cell responses have been published and applied during drug devel-
opment to reduce the risk for immunogenicity in the clinic. These include peripheral blood
mononuclear cell (PBMC)-based assays [14], dendritic cell (DC):T cell assays [15, 16] and
more complex assays where naïve T cells are amplified polyclonally [17] or antigen-specifically
[18, 19].
Numerous biological products have been approved by FDA. When reviewing the label of
these compounds, immunogenicity has been reported in 89% of the cases wherein half of these
incidences impacts the efficacy of the drug [20]. One of the most important and diverse thera-
peutic classes of BPs in the clinic are the therapeutic mAbs. Examples of mAbs with exhaustive
documented clinical immunogenicity are the anti-TNF-α mAbs infliximab (Remicade1) and
adalimumab (Humira1), as well as the anti-α4-integrin mAb natalizumab (Tysabri1). They
are all used in treatment of inflammatory disease and have been observed to have high inci-
dences (up to 87%) of ADA formation [21–23]. Rituximab, an anti-CD20 mAb used for treat-
ment of lymphoma and inflammatory diseases, shows high incidences of ADA in the latter
[24, 25].
Due to the safety issues associated with immunogenicity, it is of great importance to reduce
the risk for immunogenicity in the clinic. Currently, no pre-clinical immunogenicity tools can
predict clinical immunogenicity. Nevertheless, in this study we are trying to address the rela-
tion between an in vitro T cell assay and clinical immunogenicity. As a part of managing these
unwanted immunogenicity associated risks, an immense effort has been made by the ABIRISK
consortium (www.abirisk.eu) of the European Innovative Medicines Initiative. The major
goals of the consortium are to improve methods for immunogenicity prediction and ADA
assessment, as well as to establish common definitions and terms related to immunogenicity
[26].
Still acknowledging the caveats and limitations of immunogenicity prediction, the purpose
of the present study was to develop a high throughput and sensitive method to evaluate the
CD4+ T cell response of healthy donors to specific BPs such as neo-antigens, like therapeutic
mAbs. Based on the commonly used CD8+ T cell-depleted PBMC and DC:T cell assays we
CD4+ T cell response to biopharmaceuticals
PLOS ONE | https://doi.org/10.1371/journal.pone.0178544 May 31, 2017 2 / 17
financial support in the form of authors’ salaries
[HSS], research materials and travel costs [HSS,
AMK and CRP], as well as provided input for study
design, data collection, analysis, approval of the
manuscript and encouraged publication. The
ABIRISK project provided the antibodies used in
the study. Besides being funded by ABIRISK
project, several of the authors are employed by the
commercial company: Novo Nordisk A/S. Novo
Nordisk A/S provided support in the form of
salaries for authors [SRR, BTB, KL, CRP and AMK],
as well as provided input for study design, data
collection, analysis, and preparation of the
manuscript.
Competing interests: HSS, SRR, BTB, KL, CRP
and AMK have been or are employees of Novo
Nordisk A/S and have stocks and/or stock options
in Novo Nordisk A/S. The authors do not have any
financial competing interests. All the company-
employed authors declare that their employment
does not alter their adherence to PLOS ONE
policies on sharing data and materials.
developed a novel in vitro hybrid T cell assay that uses purified CD4+ T cells co-cultured with
irradiated PBMCs. By evaluating a cohort of 26 healthy donors for their responses to KLH,
CMV, infliximab, rituximab, adalimumab and natalizumab, in terms of proliferation and IL-2
secretion, we determined the frequency of responding donors, the magnitude of the response,
as well as the BP-specific T cell repertoire. Our novel T cell:PBMC assay demonstrated a higher
sensitivity compared to the standard CD8+ T cell-depleted PBMC assay and showed a high in
vitro immunogenicity potential for most of the BPs evaluated.
Materials and methods
Proteins
The primary antigen KLH (Thermo Fisher Scientific, Rockford, IL, USA) was prepared as fol-
lowed; KLH was dissolved in ultrapure water, left on ice for 30 minutes and dialyzed (Thermo
scientific, Rockford, IL, USA) against PBS followed by a 30 minutes centrifugation (3220 x g)
to remove undissolved particles. The final assay concentration for KLH was 30 μg/ml. Protec-
tive antigen (PA) from Bacillus anthracis (List Biological Labs, Campbell, CA, USA) was used
in the assay at a final concentration of 3 μg/ml. Cytomegalovirus pp65 protein (CMV; Miltenyi
Biotec, Lund; Sweden) was used in the assay at 2 μl/ml (concentration unknown). Infliximab
(10 mg/ml), rituximab (10 mg/ml), adalimumab (50 mg/ml) and natalizumab (20 mg/ml)
were obtained from the ABIRISK consortium (Novartis, Basel, Switzerland). The BPs were
aliqouted and stored at -80˚C according to the instructions provided. The Abs were used in
the assay at 45 μg/ml (0.3μM).
T cell assay setup
Blood donations were obtained from screened healthy volunteers via the Danish Blood Bank
under informed consent, according to the protocol H-D-2008-113 for research use approved by
the Danish Scientific Ethical Committee Region Hovedstaden (Legislative Order No. 402 of May
28th, 2008). Donations were fully anonymous to Novo Nordisk A/S employees. PBMCs were puri-
fied by Ficoll-Plaque Plus (GE Healthcare, Uppsala, Sweden) density centrifugation. Red blood
cells were lysed using RBC lysis buffer (eBioscience, San Diego, CA, USA) and the PBMCs washed
twice in PBS. A fraction of the PBMCs was γ-irradiated at 3000 rads to prevent cell division to
ensure that the responses seen solely are CD4+ T cell-mediated. From the remaining fraction,
CD4+ T cells were isolated using a CD4+ T cell enrichment kit (Easysep, Stemcell Technologies,
Grenoble, France). CD4+ T cell purity was assessed by flow cytometry and was within the range
of 93.0±4.8%. The CD4+ T cells were co-cultured at 37˚C in 5% CO2 in serum-free Optimizer
medium (Gibco, Grand Island, NY, USA) supplemented with Optimizer T-cell expansion supple-
ment, 2 mM GlutaMAX (Gibco, Grand Island, NY, USA), 50 U/ml Penicillin and 50 μg/ml Strep-
tomycin (Gibco, Grand Island, NY, USA) at a ratio 1:2 with the autologous irradiated PBMCs.
After six-eight days, proliferation and IL-2 secretion were determined.
T cell proliferation
To assess T cell proliferation, 1x105 CD4+ T cells were co-cultured with 2x105 autologous
PBMCs in 96-well plates in the absence or presence of BPs and control Ags. Cells were cul-
tured for five or seven days before being pulsed with 0.5 μCi 3[H]-thymidine (Perkin Elmer,
Groningen; Netherlands) for 18 hours. The cells were harvested using a 96-well cell FilterMate
harvester (PerkinElmer, Warrenville road IL, USA). 3[H]-thymidine incorporation was mea-
sured by liquid scintillation counting using a TopCount NXT (Perkin Elmer, Warrenville road
CD4+ T cell response to biopharmaceuticals
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IL, USA). Data was analyzed using GraphPad Prism 6.0 software (Graphpad Software version
6, La Jolla, CA, USA). Each sample was tested in sextuplicates.
IL-2 ELISpot assay
For ELISpot analysis, 5x105 CD4+ T cells were co-cultured with 1x106 autologous PBMCs in
24-well plates in the absence or presence of BPs and control antigens for six days. To all the
conditions, 5 μl/ml anti-CD28/CD49d mAbs (BD Biosciences, San Jose, CA, USA) co-stimula-
tory reagent was added. Pre-coated IL-2 ELISpot (Mabtech, Nacka Strand, Sweden) plates
were washed in PBS prior to conditioning the plate with Optimizer medium with 10% FBS
(Gibco, Grand Island, NY, USA) for 30 minutes. The cultured cells were washed twice, plated
on the ELISpot plate in triplicates and re-stimulated with the BPs. After 18 hours the ELISpot
plate was developed according to manufacturer’s instructions. Plates were scanned on an
ImmunoSpot1 S5 analyzer and the total number of spots per well (spw) was determined using
ImmunoSpot1 5.0.9 analyzer software (CLT, Inc., Shaker Heights, OH, USA).
HLA genotyping
PBMCs (1-2x106) were snap frozen on dry ice and stored at -80˚C until analysis. The PBMC
samples were shipped to ProImmune (Oxford, UK) for HLA class II typing. HLA genotyping
was performed using PCR-sequence specific oligonucleotides (PCR-SSOP) to resolve major
allele groups to 4 digits.
T cell assay analysis
Positive responses to the compounds were based on both statistical and empirical thresholds. For
the statistical threshold a positive hit was found when p<0.05 comparing counts per minute
(cpm) for T cell proliferation (n = 6) or spw for ELISpot (n = 3) of BP treated wells against baseline
wells, using a two-tailed unpaired student’s t-test (GraphPad Prism version 6, La Jolla, CA, USA).
The empirical threshold was based on a stimulation index (SI)>2, where SI was calculated from
cpmAg/cpmbaseline or spwAg/spwbaseline. For a given compound, a positive response was defined to
have SI>2 and p<0.05. The distribution of rare sets of T cell precursors has been shown to follow
a Poisson distribution [27, 28]. The frequency of BP-specific CD4+ T cells was calculated using
the following formula: Frequency = -ln(negative wells/total well tested)/(CD4+ T cells/well) [19].
Wells were scored positive when they exceeded the value> 2 x average cmpbaseline. When all wells
were positive for a T cell response we set the number of negative wells to 0.1, since the formula
cannot accept the value 0.
Results
Development of a novel T cell:PBMC assay
To develop a sensitive and high throughput T cell assay we combined and optimized the cur-
rent assays used by contract research organizations (CRO), including PBMC and DC:T cell
assays from Antitope Ltd (EpiScreenTM), Lonza (EpiBaseTM), ProImmuneLtd (REVEAL1),
EpiVax Inc. and ImmunXperts. The parameters considered were media, cell culture condi-
tions, cell number ratio, antigen-presenting cells (APCs), culture time, bulk culture vs single
well, co-stimulation, concentration, number of BP stimulations, readouts and analyses. The
optimization of the assay culture conditions was achieved using well-known immunogenic
proteins; the primary antigens KLH and PA, and the recall antigen CMV. The optimized
method is shown in a schematic overview in Fig 1. The main novelty with the assay is the
combination and ratio of purified CD4+ T cells and the use of irradiated PBMCs as APCs.
CD4+ T cell response to biopharmaceuticals
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Comparing the optimized T cell:PBMC assay with a standard CD8+ T cell-depleted PBMC
assay, an increased response to KLH, CMV and PA for both IL-2 secretion and proliferation
was observed (Fig 2). For the CD8+ T cell-depleted PBMC assay, the SI values for the antigens
were observed to be between 0.4–1.3 for IL-2 secretion and 4–5 for proliferation. Compared to
these, the SI values for the T cell:PBMC assay were approximately 10–40 fold higher with SI
values between 9–57 for IL-2 secretion and 17–51 for proliferation. By reducing the back-
ground, the T cell:PBMC assay was found to have a higher sensitivity to the model antigens
compared to CD8+ T cell-depleted PBMC assay.
Assessment of T cell response to biopharmaceuticals
By applying our optimized assay, cells from a cohort of 26 healthy volunteers were exposed to
the four mAbs (listed in Table 1). Each donor was assessed by determining their individual
responses to the controls and BPs, respectively. A representative example of a donor is given in
Fig 3. This donor was observed to respond positively to KLH, CMV and natalizumab by
means of proliferation, and to KLH, CMV, rituximab and natalizumab in terms of IL-2 secre-
tion. Hence, based on the summary of positive responses in these two assays, this donor was
stated to respond positively to KLH, CMV, rituximab and natalizumab.
Magnitude of T cell response to biopharmaceuticals
The abovementioned way of calculating responding donors reduces the data into a positive/
negative distribution and does not consider the strength of the response. Therefore, the mean
Fig 1. A novel T cell:PBMC assay to detect CD4+ T cell response to BPs in healthy donors. The figure shows a schematic representation of the T cell:
PBMC assay format: PBMCs were obtained from naive healthy donors. CD4+ T cells were enriched and plated in 24-well or 96-well plates at respectively
5x105 or 1x105 cells/well in multiple wells containing irradiated allogeneic PBMC at a concentration of either 2x105 or 1x106 cells/well. The co-cultured cells
were challenged with KLH (30 μg/ml), CMV (2 μl/ml), infliximab, rituximab, adalimumab and natalizumab (all 45 μg/ml). To the 24-wells for ELISpot analysis
5 μl/ml anti-CD28/CD49d mAbs were added. At day six, the 24-well cell cultures were washed thoroughly, re-stimulated with the corresponding compounds
and plated in triplicates in 96-well plates for 18 hours prior to spot detection. At day six and eight, proliferation (n = 6) was measured after 18-h pulse with 3[H]-
thymidine. Reprint from Servier Medical Art by Servier under a CC BY license with permission from Servier Medical Art, original copyright Creative Commons
Attribution 3.0 Unported License.
https://doi.org/10.1371/journal.pone.0178544.g001
CD4+ T cell response to biopharmaceuticals
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Fig 2. Responses to KLH, PA and CMV. PBMCs from a healthy donor were isolated and used for both (A)
CD8+ T cell-depleted PBMC assay and (B) our optimized T cell:PBMC assay. The cultures were challenged
with keyhole limpet hemocyanin (KLH, 30 μg/ml), Protective antigen (PA, 3 μg/ml) and cytomegalovirus
(CMV, 2μl/ml). Proliferation was measured by 3[H]-thymidine incorporation at day six and IL-2 secretion was
measured by ELISpot analysis at day seven. The proliferative response in counts per minute (cpm) and
ELISpot IL-2 secretion (spw) was converted to stimulation index (SI). Shown are graphs of SI of proliferation
and IL-2 secretion, which is also visualized by pictures. Shown is one representative donor out of four.
https://doi.org/10.1371/journal.pone.0178544.g002
Table 1. Summary of research data and characteristics of BPs from European clinical trials and studies.
In vitro response (present study) Clinical and study data
BP name Route of
injection
Target Frequency of responding
donors (%)
Per 106
cells
Indication ADA response
(%)
References
Infliximab (chimeric) IV TNF-α 3.8 0.2 RA 13–44 [29–31]
Crohn’s disease 61 [32]
Cutaneous systemic
sclerosis
31 [33]
AS 29 [34]
Rituximab (chimeric) IV CD20 19.2 0.6 RA 9 [35]
SLE 36 [36]
Primary Sjogren’s
syndrome
27 [37]
Vasculitis 25 [36]
Severe pemphigus 18 [38]
Adalimumab
(human)
SC TNF-α 7.7 0.4 RA 2–87 [31, 39, 40]
AS 22.4 [41]
Natalizumab
(humanized)
IV α4-integrin 26.9 2.2 MS 4–5 [23, 42]
RA: Rheumatoid arthritis; AS: Ankylosing spondylitis; MS: Multiple sclerosis; SLE: Systemic lupus erythematosus; IV: intravenous injection; SC:
subcutaneous injection
https://doi.org/10.1371/journal.pone.0178544.t001
CD4+ T cell response to biopharmaceuticals
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SI value of the entire study population was also examined. Fig 4 shows the magnitude for the
individual donors for each test compound for proliferation and IL-2 secretion, respectively. Of
the tested compounds, the positive controls, KLH and CMV, had the highest mean SI responses,
ranging between 45–65 and 10–180, respectively. Of the BPs, infliximab, rituximab, adalimu-
mab and natalizumab had a correspondingly mean SI value of 1.0, 1.2, 1.2 and 1.8 in average for
proliferation (Fig 4A and 4B). For IL-2 secretion the mean SI value was highest for rituximab
with a mean SI value of 5.2, followed natalizumab with 1.3, adalimumab with 0.9 and infliximab
with 0.6 (Fig 4C).
Evaluation of frequency of BP-specific CD4+ T cells in healthy donors
Based on proliferation at both day six and eight, we assessed the frequency of CD4+ T cells spe-
cific to the BPs (Fig 5). As described in the method sections, the calculations for determining
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Fig 3. Example of a donor. One representative donor’s response to KLH (30 μg/ml), CMV (2 μl/ml), infliximab, rituximab, adalimumab and
natalizumab (all 45 μg/ml) was assessed in the T cell:PBMC assay. The ability to elicit an Ag-specific response was detected by proliferation and IL-
2 ELISpot. The response to untreated is included as a negative control. Proliferation was measured by 3[H]-thymidine incorporation in sextuplet at
(A) day six and (B) day eight, shown as stimulation index. IL-2-producing T cells were identified by ELISpot analysis as shown by (C) stimulation
index and as (D) visualized by pictures. The statistical difference indicated is based on raw data; cpm for T cell proliferation (n = 6) or spw for ELISpot
(n = 3) using an unpaired student t test.
https://doi.org/10.1371/journal.pone.0178544.g003
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Fig 4. Mean magnitude of the BPs in the test population. Scatter plot summarizing the mean stimulation index value of all the donors in the
study population. Shown is (A) proliferation day six, (B) proliferation day eight and (C) IL-2 secretion. The dotted line indicates SI = 2, which is the
cut-off value for a positive response.
https://doi.org/10.1371/journal.pone.0178544.g004
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the frequency of BP-specific CD4+ T cells is based on negative wells, and since all the donors
in all wells responded positively to CMV, we could not estimate a frequency for this control.
KLH demonstrated a strong T cell response, as the mean T cell frequency for KLH was 40.7
cells/106 cells. The CD4+ T cell repertoire to the BPs was significantly lower, since the fre-
quency of responding cells were 0.2 BP-specific CD4+ T cells/106 cells specific to infliximab,
0.6 cells/106 cells for rituximab, 0.4 cells/106 cells for adalimumab and 2.2 cells/106 cells for
natalizumab.
HLA-DR, DP and DQ haplotype frequencies
The donors included in our study population were typed for the MHC class II alleles HLA-
DR, -DP and -DQ to determine the representation of the population, see Table 2. The exami-
nation revealed that the study population covered all major HLA-DR, DP and DQ allotypes.
To further assess the distribution of our analyzed donors, we compared the study population
to the distribution of the European and North American population in terms of HLA-DRB1
(Fig 6). The donors showed multiple HLA-DRB1 allotypes, including the most frequent alleles
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Fig 5. Frequencies of CD4+ T cells specific to the BPs. The frequency of CD4+ T cell specific for KLH,
CMV, Infliximab, Rituximab, Adalimumab and Natalizumab expressed per 106 naïve CD4+ T cell for the
individual donors as well as the mean (± SEM) is indicated. The data is based on pooled data from proliferation
at day six and eight from all 26 donors. The mean number of BP-specific CD4+ T cells identified is specified at
the top of each histogram.
https://doi.org/10.1371/journal.pone.0178544.g005
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Table 2. A summary of the high resolution HLA-DR, DQ and DP haplotypes of the included donors in the assay.
Donor DRB1-
1
DRB1-
2
DRB3-
1
DRB3-
2
DRB4-
1
DRB4-
2
DRB5-
1
DRB5-2 DQB1-
1
DQB1-
2
DQA1-
1
DQA1-2 DPB1-
1
DPB1-
2
DPA1-
1
DPA1-
2
1 *13:02 *15:01 *03:01 - - - *01:01 - *06:02 *06:04 *03:01 *04:01 *01:01 *01:02 *01:03 -
2 *03:01 *04:04 *01:01 - *01:01 - - - *02:01 *03:02 *04:01 *04:02 *03:01 *05:01 *01:03 -
3 *12:01 *15:01 *02:02 - - - *01:01 - *03:01 *06:02 *04:02 *05:01 *01:01 *05:01 *01:03 *02:02
4 *11:01 *15:01 *02:02 - - - *01:01 - *03:01 *06:02 *04:02 *05:01 *01:01 *05:01 *01:03 -
5 *04:01 *04:04 - - *01:01 - - - *03:02 - *03:01 - *03:01 - *01:03 -
6 *13:02 *14:01 *02:02 *03:01 - - - - *05:03 *06:04 *04:01 - *01:01 *01:02 *01:03 -
7 *13:01 *14:01 *01:01 *02:02 - - - - *05:03 *06:03 *04:01 *04:02 *01:01 *01:03 *01:03 -
8 *03:01 *04:04 *01:01 - *01:01 - - - *02:01 *03:02 *01:01 *03:01 *03:01 *05:01 *01:03 *02:01
9 *03:01 *07:01 *02:02 - *01:03 - - - *02:01 *03:03 *04:01 - *02:01 *05:01 *01:03 -
10 *07:01 *13:01 *01:01 - *01:01 - - - *02:02 *06:03 *02:01 - *01:03 *02:01 *01:03 -
11 *01:01 *13:02 *03:01 - - - - - *05:01 *06:04 *06:01 *09:01 *01:01 *01:02 *01:03 *02:01
12 *04:04 *04:07 - - *01:01 - - - *03:01 *03:02 *03:01 *19:01 *03:01 - *01:03 *02:02
13 *07:01 *10:01 - - *01:01 - - - *02:02 *05:01 *02:01 *11:01 *01:01 *02:01 *01:03 *02:01
14 *03:01 *13:02 *01:01 *03:01 - - - - *02:01 *06:04 *04:01 - *01:02 *05:01 *01:03 -
15 *01:01 *07:01 - - *01:03 - - - *03:03 *05:01 *04:01 *10:01 *01:01 *02:01 *01:03 *02:01
16 *03:01 *04:01 *01:01 - *01:01 - - - *02:01 *03:02 *04:01 - *03:01 *05:01 *01:03 -
17 *15:01 - - - - - *01:01 - *06:02 - *03:01 *15:01 *01:01 - *01:03 *01:04
18 *11:01 *13:01 *01:01 *02:02 - - - - *03:01 *06:03 *02:01 *04:02 *01:03 *05:01 *01:03 -
19 *07:01 *15:01 - - *01:03 - *01:01 - *03:03 *06:02 *04:01 - *01:02 *02:01 *01:03 -
20 *01:01 *01:02 - - - - - - *05:01 - *02:01 *03:01 *01:01 - *01:03 -
21 *01:01 *07:01 - - *01:01 - - - *02:02 *05:01 *04:01 *11:01 *01:01 *02:01 *01:03 *02:01
22 *04:01 *04:04 - - *01:01 - - - *03:02 - *02:01 *04:02 *03:01 - *01:03 -
23 *01:01 *15:01 - - - - *01:01 - *05:01 *06:02 *02:01 *04:01 *01:01 *01:02 *01:03 -
24 *04:04 *15:01 - - *01:01 - *01:01 - *03:02 *06:02 *04:01 - *01:02 *03:01 *01:03 -
25 *04:04 *14:01 *02:02 - *01:01 - - - *03:02 *05:03 *03:01 *04:01 *01:01 *03:01 *01:03 -
26 *04:01 *13:02 *03:01 - *01:01 - - - *03:01 *06:04 *02:01 *04:01 *01:02 *03:01 *01:03 -
https://doi.org/10.1371/journal.pone.0178544.t002
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Fig 6. Frequency of donor HLA-DRB1. Comparison of the frequency of high resolution HLA-DRB1 allotypes
expressed in the test population versus the; A) the European population and B) the North American population.
The correlation was calculated using Pearson correlation coefficient.
https://doi.org/10.1371/journal.pone.0178544.g006
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present in the European population, where the correlation of frequencies in the populations
was significant. This was not observed for the North American population.
Responding donors
The frequency of responding donors was calculated based on either proliferation or IL-2 secre-
tion in the 26 donors (Fig 7). A similar approach has recently been demonstrated to correlate
with the rate of clinical immunogenicity of biotherapeutic mAbs [43]. The naïve antigen KLH
and the recall antigen CMV induced a response in all the donors analysed. Infliximab, rituxi-
mab, adalimumab and natalizumab, stimulated a response in 4%, 19%, 8% and 27% of the study
population, respectively. To provide an assessment of the relative risk of each of the BPs to
induce a T cell response, both the frequency of responders and the magnitude of the response
was considered. Therefore, the percentage of responding donors was plotted against the mean
SI of the responding donors in a heat plot (Fig 8). The BPs in the upper right region have a
higher T cell response than the BPs in the lower left region. The results from this assay suggest
that natalizumab and rituximab have a higher immunogenicity potential than adalimumab and
infliximab. It shall be mentioned that one of the donors had a very high SI value for rituximab,
which skewed the result in the plot.
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Fig 7. Frequency of responding donors. Summary of CD4+ T cell response to BPs among 26 donors.
Donors were considered to be positive responders if one of both of the two proliferation assays, and/or the IL-
2 secretion assay, showed a SI>2 with p<0.05 for a given donor’s response to a given BP compared to the
respective control assay result.
https://doi.org/10.1371/journal.pone.0178544.g007
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Discussion
Given the impact of immunogenicity on safety and efficacy of BPs, there is a rising interest in
developing methods that clarify the immunogenic risks linked to therapeutic proteins [26].
For generation of high affinity ADAs, the process relies on T cell-dependent mechanisms. It
has therefore been suggested that evaluating the presence of T cell epitopes by in vitro T cell
assays in healthy donors can anticipate the risk of immunogenicity. Several considerations
need to be accounted for when setting up such an assay. These include high sensitivity, high
throughput and access to donor cohorts with HLA allotypes covering the most frequent HLA
class II alleles in the major populations.
We chose to develop an assay that was based on CD4+-enriched T cells and irradiated
PBMCs comprising the APC population, which is novel compared to the currently used
CD8-depleted PBMC assay or DC:T cell assay. When using enriched CD4+ T cells instead of
CD8+ T cell-depleted PBMCs, the amount of CD4+ T cells added to each well can be con-
trolled, which is needed for T cell repertoire frequency calculations. Cytokine contribution
from non-specific cells can also be limited. Using PBMCs as APCs eliminates the time used to
generate DCs hence allowing high throughput. To quantify the T cell response, two indepen-
dent readouts for T cell activation were exploited; T cell proliferation measured by 3[H]-thymi-
dine incorporation and IL-2 secretion detected by ELISpot. A major challenge for in vitro
immunogenicity prediction assays for BPs is the weak response. A high sensitivity is needed
since frequencies of naïve T cells specific for a foreign antigen are in the range of 0.3–70 cells/
106 [17, 44, 45]. Few donors responded to the BPs when assessing proliferation by thymidine
incorporation. The limitation with this method is that it only conveys a snapshot of what hap-
pens, and consequently events occurring at an earlier or later time-point can be missed. An
alternative to increase sensitivity could be a flow cytometry-based approach using CFSE label-
ling, Ki67 expression or EdU incorporation [46]. In contrast, ELISpot is a highly sensitive
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Fig 8. Plot of T cell response to the BPs. The frequency of responding donors and their mean IL-2 secretion
and proliferation stimulation index (SI) levels. Donors were considered to be positive responders if one or both
of the two proliferation assays, and/or the IL-2 secretion assay, showed an SI>2 with P<0.05 for a given donor’s
response to a given BP compared to the respective control assay result. The mean SI for IL-2 secretion and
proliferation levels for these positive responders are plotted against the % of positive responders for each BP.
https://doi.org/10.1371/journal.pone.0178544.g008
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method that allows for detection of a single cell that secrets a protein [47, 48]. Most positive
responses were thus captured with this method. Other contributing factors to the increased
sensitivity of the ELISpot assay could be the addition of the co-stimulatory anti-CD28/CD49d
Abs and the re-challenge with BPs, which were not applied in the proliferation assay. To distin-
guish responding donors from non-responding donors we used a combination of two criteria,
SI and statistical difference. A SI value above 2 was defined a positive response, which is equiv-
alent to other similar studies that have defined their SI cut-off value ranging from 1.8 to 3 [16,
49, 50]. The SI value was pre-set to be above 2 to achieve minimum signal-to-noise, maximum
sensitivity and limit false positive events.
To evaluate the performance of the T cell:PBMC assay, we assessed 26 healthy, drug-naïve
donors for their T cell response to KLH, CMV and the BPs. Use of healthy drug-naïve donors
are current practice in the field of Ab analysis, as they better reflect the patient population
compared with BP-treated patients that already have developed ADAs. Moreover, as most of
the BPs are used for treatment of several diseases, each with different co-medication that can
affect the ADA response, we wanted to evaluate the assay independent of disease indication,
which again could have impact on the correlation between T cell assay and ADA development
[50]. The haplotype of the donors included in the study were determined retrospectively and
was found to have a frequency of HLA-DRB1 types that correlated to the European popula-
tion. HLA class II molecules determine the sequence of the peptides that can be bound and
presented to the T cells, and it is therefore essential to identify the population for which the
HLA profile is relevant [7]. Since the current study population represents the European popu-
lation, the results were subsequently compared to ADA incidences reported in Europe, as
noted in Table 1.
One of the approaches to evaluate the T cell response was to calculate the number of BP-
specific T cells. The magnitude of the T cell response to mAbs has recently been demonstrated
to depend on the number of pre-existing antigen-specific T cells [19]. In the current study, the
KLH-specific T cell repertoire was calculated to be 41 cells/106 cells, which is similar to other
studies that have reported the KLH-specific T cell frequency to be 19–42 [51], 5–30 [19] and
10–70 cells per 106 CD4+ T cells [17]. The frequency of BP-specific CD4+ T cells was found to
be in the range of 0.2–2.2 cells/106 CD4+ T cells, which correlates well with the findings of Del-
luc and colleagues [19]. They observed a frequency of CD4+ T cells to infliximab, rituximab
and adalimumab to be 0.2, 0.4 and 0.3 cells/106 T cells, respectively. For the mAbs, the T cell
responses are largely mediated by naïve T cells [19] due to the foreignness of the complemen-
tarity determining regions (CDRs) and for some donors the frame work as well, but it could
also be caused by memory cells as many patients have pre-existing Abs, including rheumatoid
factors, anti-allotype, anti-hinge and anti-glycan Abs [52].
A direct comparison of in vitro T cell responses to clinical data cannot be conducted as
many factors complicate the determination of the “true” immunogenicity of a BP, including
differences in clinical trial testing, time-frame over which the ADA response is measured, use
of different ADA assays and differences in reporting. An example is rituximab treatment that
is well accepted in cancer patients [53, 54], but not in systemic lupus erythematosus patients,
since in the latter ADA responses are found in up to 36% of the patients [36]. In the current
assay, rituximab was observed to stimulate a response in 19% of the donors analyzed. Consid-
ering both the frequency and the magnitude of the response, the assay predicts rituximab to be
immunogenic, which correlates well with the overall clinical picture (Table 1). For infliximab
and adalimumab on the other hand, surprisingly low frequencies of responding donors were
found; 4% and 8%, respectively. The occurrence of ADAs in the clinic to infliximab and adali-
mumab is generally high, ranging from 4–87% for patients with autoimmune diseases. More-
over, based on the degree of foreignness, infliximab can be expected to induce a higher T cell
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response than adalimumab since adalimumab is fully human and infliximab is chimeric and
therefore has more non-human sequences. However, an important factor is the mode of action
of the BP in question. Many BPs can modulate the T cell response directly or affect the APCs,
hence potentially influence Ag-uptake, presentation and cytokine profile [55, 56]. Anti-TNF-α
mAbs have been shown to affect the maturation and survival of APCs, as well as suppress T
cell proliferation [57, 58]. Therefore, TNF-α inhibitors are likely to interfere with the assay,
resulting in suppressed proliferation and consequently an underestimated response. Two
recent papers have assessed the in vitro T cell response to rituximab, infliximab and adalimu-
mab using either the EpiScreenTM DC:T cell assay or the EpiScreenTM Time Course T cell
(PBMC) assay at Antitope Ltd. [43, 50]. Karle et al. observed that the mAbs had the ability to
initiate a T cell response in 10, 14 and 20% of the donors for rituximab, adalimumab and
infliximab, respectively [50], whereas Joubert et al. observed rituximab, adalimumab and
infliximab to induce a response in 10, 21 and 14% of the analyzed donors [43]. These discrep-
ancies underline the difficulties in assessing the immunogenicity potential of Abs binding to
targets affecting immune cells. Furthermore, natalizumab was found to induce a response in
27% of the donors. Natalizumab is in general believed to be a weak immunogen with detected
Abs in 4–5% in phase I and II studies with patients with multiple sclerosis. [42]. However,
these numbers are likely underestimated as the long-term immunogenicity of natalizumab is
unknown. Indeed, recent studies conducted within the ABIRISK project show that natalizu-
mab generates ADAs in a much higher frequency than previously reported (unpublished data
by ABIRISK).
Due to the abovementioned factors, it is difficult to predict the clinical immunogenicity
with an in vitro T cell assay. However, it gives the possibility to assess whether the compounds
have the capacity to induce a T cell response. The test compounds should be viewed individu-
ally and not ranked against each other. Even though the target is the same, as for infliximab
and adalimumab, formulation and injection routes are different, which likely also influence
the clinical immunogenicity. Rather, in vitro T cell assays can be used to support lead candidate
selection during drug development by choosing a variant with a low T cell response.
In conclusion, we have developed a novel T cell:PBMC assay that can evaluate the immuno-
genicity potential of BPs. It has the capability of detecting low frequencies of BP-specific T cells,
and demonstrates a high in vitro immunogenicity to several BPs with a documented high clini-
cal immunogenicity. The assay provides information that in conjugation with other immunoge-
nicity prediction tools can be used in early drug development to select drug candidates with low
immunogenicity potential to ultimately increase patient safety.
Supporting information
S1 File. Written information regarding granted permission to publish Fig 1.
(DOCX)
Acknowledgments
The research leading to these results was conducted as a part of the ABIRISK consortium. Pro-
vided below is a list of the individual authors and their affiliations. Medizinische Universita¨t
Innsbruck (Florian Deisenhammer), UCB Pharma SA (Louis Christodoulou), GlaxoSmithKline
(Dan Sikkema, Amy Loercher, Julie Davidson, Andy Lawton, Steve Etheridge, Sally Miles),
INSERM (Marc Pallardy, Sophie Tourdot, Xavier Mariette, Sebastien Lacroix-Desmazes, Phi-
lippe Broet, Delphine Bachelet, Nadia El-Hamdi), Academisch Medisch Centrul bij de Universi-
teit van Amsterdam (Niek De Vries, Anne Musters), Assistance Publique Hopitaux de Paris
CD4+ T cell response to biopharmaceuticals
PLOS ONE | https://doi.org/10.1371/journal.pone.0178544 May 31, 2017 13 / 17
(Aline Doublet), Groupe d’e´tudes the´rapeutiques des affections inflammatoires du tube digestif
(Matthieu Allez, Sabrina Williams), Universitaetsklinikum Bonn (Johannes Oldenburg, Thilo
Albert), Karolinska Institutet (Anna Fogdell Hahn, Malin Ryner, Ryan Ramanujam), Pfizer
(Tim Hickling), Merck Serono (Elisa Bertotti), Ipsen (Julie Le Grand), University College Lon-
don (Claudia Mauri, Liz Jury), Sanofi-Aventis Research and Development (Vincent Mikol,
Agnès Hincelin-Mery, Catherine Prades, Pauline Loas), Università di Firenze (Enrico Maggi),
Novartis Pharma AG (Annette Karle, Sebastian Spindeldreher (work package 3 co-leader), Ver-
ena Romach-Riegraf), Fondazione per l’Istituto di Ricerca in Biomedicina (Antonio Lanzavec-
chia), Klinikum rechts der Isar der Technischen Universitaet Muenchen (Bernhard Hemmer),
Commissariat à l’Energie Atomique (Bernard Maillere; work package 3 co-leader), Novo Nor-
disk (Christian Ross Pedersen; work package 3 co-leader, email: christian.ross.pedersen@re-
gionh.dk), Scicross AB (Pierre Do¨nnes), Bayer Schering Pharma AG (Jeannette Lo, Pascale
Buchmann), eTRIKS (Fabien Richard), Paul-Ehrlich-Institut (Christine Keipert), ALTA Ricerca
e Sviluppo in Biotecnologie S.r.l.u. (Riccardo Bertini, Simona Farnetani).
Graphics in Fig 1 has been adapted from Servier Medical Art (www.servier.com).
Johanna Davidsson kindly checked the manuscript for linguistic errors.
Author Contributions
Conceptualization: AMK CRP BTB SLR KL HSS.
Data curation: HSS AMK.
Formal analysis: HSS AMK.
Funding acquisition: AMK SLR CRP BTB.
Investigation: HSS AMK.
Methodology: HSS AMK SLR BTB.
Project administration: CRP KL AMK HSS.
Resources: CRP KL.
Supervision: AMK KL.
Validation: CRP.
Visualization: HSS AMK.
Writing – original draft: HSS AMK.
Writing – review & editing: HSS AMK SLR BTB KL CRP.
References
1. Tovey MG, Legrand J, Lallemand C. Overcoming immunogenicity associated with the use of biophar-
maceuticals. Expert Rev Clin Pharmacol. 2011; 4(5):623–31. https://doi.org/10.1586/ecp.11.39 PMID:
22114889
2. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and
antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;
346(7):469–75. https://doi.org/10.1056/NEJMoa011931 PMID: 11844847
3. Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biologics in IBD—the role
of patient, product and prescriber factors. Aliment Pharmacol Ther. 2013; 38(10):1188–97. https://doi.
org/10.1111/apt.12507 PMID: 24118102
4. Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci. 2011;
100(2):354–87. https://doi.org/10.1002/jps.22276 PMID: 20740683
CD4+ T cell response to biopharmaceuticals
PLOS ONE | https://doi.org/10.1371/journal.pone.0178544 May 31, 2017 14 / 17
5. Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunoge-
nicity of protein therapeutics: Preclinical assessment and mitigation. Clin Immunol. 2013; 149(3):534–
55. https://doi.org/10.1016/j.clim.2013.09.006 PMID: 24263283
6. Pratt KP, Thompson AR. B-cell and T-cell epitopes in anti-factor VIII immune responses. Clin Rev
Allergy Immunol. 2009; 37(2):80–95. https://doi.org/10.1007/s12016-009-8120-7 PMID: 19184559
7. Stickler M, Valdes AM, Gebel W, Razo OJ, Faravashi N, Chin R, et al. The HLA-DR2 haplotype is asso-
ciated with an increased proliferative response to the immunodominant CD4(+) T-cell epitope in human
interferon-beta. Genes Immun. 2004; 5(1):1–7. https://doi.org/10.1038/sj.gene.6364027 PMID:
14735143
8. Barbosa MD, Vielmetter J, Chu S, Smith DD, Jacinto J. Clinical link between MHC class II haplotype
and interferon-beta (IFN-beta) immunogenicity. Clin Immunol. 2006; 118(1):42–50. https://doi.org/10.
1016/j.clim.2005.08.017 PMID: 16260183
9. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: The key
causes, consequences and challenges. Self Nonself. 2010; 1(4):314–22. PubMed Central PMCID:
PMCPMC3062386. https://doi.org/10.4161/self.1.4.13904 PMID: 21487506
10. Jones TD, Phillips WJ, Smith BJ, Bamford CA, Nayee PD, Baglin TP, et al. Identification and removal of
a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J Thromb Haemost. 2005; 3
(5):991–1000. https://doi.org/10.1111/j.1538-7836.2005.01309.x PMID: 15869596
11. Weber CA, Mehta PJ, Ardito M, Moise L, Martin B, De Groot AS. T cell epitope: friend or foe? Immuno-
genicity of biologics in context. Adv Drug Deliv Rev. 2009; 61(11):965–76. https://doi.org/10.1016/j.
addr.2009.07.001 PMID: 19619593
12. Yeung VP, Chang J, Miller J, Barnett C, Stickler M, Harding FA. Elimination of an immunodominant
CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdomi-
nant epitope. J Immunol. 2004; 172(11):6658–65. PMID: 15153481
13. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human
antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010; 2(3):256–65. PubMed
Central PMCID: PMCPMC2881252. PMID: 20400861
14. Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson S, et al. Considerations for optimization
and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics.
Clin Immunol. 2010; 137(1):5–14. https://doi.org/10.1016/j.clim.2010.06.018 PMID: 20708973
15. Moser JM, Sassano ER, Leistritz del C, Eatrides JM, Phogat S, Koff W, et al. Optimization of a dendritic
cell-based assay for the in vitro priming of naive human CD4+ T cells. J Immunol Methods. 2010; 353
(1–2):8–19. https://doi.org/10.1016/j.jim.2009.11.006 PMID: 19925804
16. Stickler M, Rochanayon N, Razo OJ, Mucha J, Gebel W, Faravashi N, et al. An in vitro human cell-
based assay to rank the relative immunogenicity of proteins. Toxicol Sci. 2004; 77(2):280–9. https://doi.
org/10.1093/toxsci/kfh021 PMID: 14691215
17. Geiger R, Duhen T, Lanzavecchia A, Sallusto F. Human naive and memory CD4+ T cell repertoires
specific for naturally processed antigens analyzed using libraries of amplified T cells. J Exp Med. 2009;
206(7):1525–34. PubMed Central PMCID: PMCPMC2715094. https://doi.org/10.1084/jem.20090504
PMID: 19564353
18. Delluc S, Ravot G, Maillere B. Quantification of the preexisting CD4 T-cell repertoire specific for human
erythropoietin reveals its immunogenicity potential. Blood. 2010; 116(22):4542–5. https://doi.org/10.
1182/blood-2010-04-280875 PMID: 20702780
19. Delluc S, Ravot G, Maillere B. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic
antibodies in healthy donors. FASEB J. 2011; 25(6):2040–8. https://doi.org/10.1096/fj.10-173872
PMID: 21368101
20. Wang YM, Wang J, Hon YY, Zhou L, Fang L, Ahn HY. Evaluating and Reporting the Immunogenicity
Impacts for Biological Products-a Clinical Pharmacology Perspective. AAPS J. 2016; 18(2):395–403.
https://doi.org/10.1208/s12248-015-9857-y PMID: 26721560
21. Baker M, Carr F. Pre-clinical considerations in the assessment of immunogenicity for protein therapeu-
tics. Curr Drug Saf. 2010; 5(4):308–13. PMID: 20615174
22. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. Formation
of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clini-
cal responses in rheumatoid arthritis. Ann Rheum Dis. 2009; 68(11):1739–45. https://doi.org/10.1136/
ard.2008.092833 PMID: 19019895
23. Lundkvist M, Engdahl E, Holmen C, Moverare R, Olsson T, Hillert J, et al. Characterization of anti-natali-
zumab antibodies in multiple sclerosis patients. Mult Scler. 2013; 19(6):757–64. https://doi.org/10.1177/
1352458512462920 PMID: 23045379
CD4+ T cell response to biopharmaceuticals
PLOS ONE | https://doi.org/10.1371/journal.pone.0178544 May 31, 2017 15 / 17
24. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel
treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis
Rheum. 2004; 50(8):2580–9. https://doi.org/10.1002/art.20430 PMID: 15334472
25. Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, et al. A multicenter phase I/
II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol. 2007; 17(3):191–7.
https://doi.org/10.1007/s10165-007-0565-z PMID: 17564773
26. Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P, et al. Standardizing terms, definitions and
concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommen-
dations of the Innovative Medicines Initiative ABIRISK consortium. Clin Exp Immunol. 2015; 181
(3):385–400. PubMed Central PMCID: PMCPMC4557374. https://doi.org/10.1111/cei.12652 PMID:
25959571
27. Wolfl M, Greenberg PD. Antigen-specific activation and cytokine-facilitated expansion of naive, human
CD8+ T cells. Nat Protoc. 2014; 9(4):950–66. PubMed Central PMCID: PMCPMC4312138. https://doi.
org/10.1038/nprot.2014.064 PMID: 24675735
28. Miller RA. Quantitation of functional T cells by limiting dilution. Curr Protoc Immunol. 2001;Chapter 3:
Unit 3 15.
29. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring
of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necro-
sis factor alpha inhibitor infliximab. Arthritis Rheum. 2006; 54(12):3782–9. https://doi.org/10.1002/art.
22214 PMID: 17133559
30. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinflix-
imab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis
Rheum. 2006; 54(3):711–5. https://doi.org/10.1002/art.21671 PMID: 16508927
31. Eng GP, Bendtzen K, Bliddal H, Stoltenberg M, Szkudlarek M, Fana V, et al. Antibodies to infliximab
and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study.
Arthritis. 2015; 2015:784825. PubMed Central PMCID: PMCPMC4339793. https://doi.org/10.1155/
2015/784825 PMID: 25759761
32. Baert F, Noman M, Vermeire S, Van Assche G, G DH, Carbonez A, et al. Influence of immunogenicity
on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003; 348(7):601–8. https://
doi.org/10.1056/NEJMoa020888 PMID: 12584368
33. Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X, et al. An open-label pilot study of inflix-
imab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2009; 68(9):1433–9. https://doi.
org/10.1136/ard.2008.096123 PMID: 18782794
34. de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA, et al. Decreased
clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann
Rheum Dis. 2007; 66(9):1252–4. PubMed Central PMCID: PMCPMC1955152. https://doi.org/10.1136/
ard.2007.072397 PMID: 17472991
35. Thurlings RM, Teng O, Vos K, Gerlag DM, Aarden L, Stapel SO, et al. Clinical response, pharmacoki-
netics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab
treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2010; 69(2):409–12. https://doi.org/10.
1136/ard.2009.109041 PMID: 19596693
36. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory
systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum.
2006; 54(9):2970–82. https://doi.org/10.1002/art.22046 PMID: 16947528
37. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treat-
ment in patients with primary Sjogren’s syndrome: an open-label phase II study. Arthritis Rheum. 2005;
52(9):2740–50. https://doi.org/10.1002/art.21260 PMID: 16142737
38. Schmidt E, Hennig K, Mengede C, Zillikens D, Kromminga A. Immunogenicity of rituximab in patients
with severe pemphigus. Clin Immunol. 2009; 132(3):334–41. https://doi.org/10.1016/j.clim.2009.05.007
PMID: 19502112
39. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response
to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in
rheumatoid arthritis. Ann Rheum Dis. 2007; 66(7):921–6. PubMed Central PMCID: PMCPMC1955110.
https://doi.org/10.1136/ard.2006.065615 PMID: 17301106
40. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and
adverse events of adalimumab in RA patients. Rheumatol Int. 2007; 27(3):269–74. https://doi.org/10.
1007/s00296-006-0183-7 PMID: 17006705
41. Kneepkens EL, Wei JC, Nurmohamed MT, Yeo KJ, Chen CY, van der Horst-Bruinsma IE, et al. Immu-
nogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks
CD4+ T cell response to biopharmaceuticals
PLOS ONE | https://doi.org/10.1371/journal.pone.0178544 May 31, 2017 16 / 17
of follow-up. Ann Rheum Dis. 2015; 74(2):396–401. https://doi.org/10.1136/annrheumdis-2013-204185
PMID: 24326011
42. Holmen C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, et al. A Swedish national post-
marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler. 2011; 17
(6):708–19. https://doi.org/10.1177/1352458510394701 PMID: 21228027
43. Joubert MK, Deshpande M, Yang J, Reynolds H, Bryson C, Fogg M, et al. Use of In Vitro Assays to
Assess Immunogenicity Risk of Antibody-Based Biotherapeutics. PLoS One. 2016; 11(8):e0159328.
https://doi.org/10.1371/journal.pone.0159328 PMID: 27494246
44. Jenkins MK, Moon JJ. The role of naive T cell precursor frequency and recruitment in dictating immune
response magnitude. J Immunol. 2012; 188(9):4135–40. PubMed Central PMCID: PMCPMC3334329.
https://doi.org/10.4049/jimmunol.1102661 PMID: 22517866
45. Maillere B. Comment on "The role of naive T cell precursor frequency and recruitment in dictating
immune response magnitude". J Immunol. 2013; 190(5):1895. https://doi.org/10.4049/jimmunol.
1290079 PMID: 23417524
46. Mannering SI, Morris JS, Jensen KP, Purcell AW, Honeyman MC, van Endert PM, et al. A sensitive
method for detecting proliferation of rare autoantigen-specific human T cells. J Immunol Methods.
2003; 283(1–2):173–83. PMID: 14659909
47. Karlsson AC, Martin JN, Younger SR, Bredt BM, Epling L, Ronquillo R, et al. Comparison of the ELI-
SPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol
Methods. 2003; 283(1–2):141–53. PMID: 14659906
48. Anthony DD, Milkovich KA, Zhang W, Rodriguez B, Yonkers NL, Tary-Lehmann M, et al. Dissecting the
T Cell Response: Proliferation Assays vs. Cytokine Signatures by ELISPOT. Cells. 2012; 1(2):127–40.
PubMed Central PMCID: PMCPMC3901088. https://doi.org/10.3390/cells1020127 PMID: 24710419
49. Mascarenhas RE, Brodskyn C, Barbosa G, Clarencio J, Andrade-Filho AS, Figueiroa F, et al. Peripheral
blood mononuclear cells from individuals infected with human T-cell lymphotropic virus type 1 have a
reduced capacity to respond to recall antigens. Clin Vaccine Immunol. 2006; 13(5):547–52. PubMed
Central PMCID: PMCPMC1459653. https://doi.org/10.1128/CVI.13.5.547-552.2006 PMID: 16682474
50. Karle A, Spindeldreher S, Kolbinger F. Secukinumab, a novel anti-IL-17A antibody, shows low immuno-
genicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clini-
cal immunogenicity. MAbs. 2016; 8(3):536–50. https://doi.org/10.1080/19420862.2015.1136761 PMID:
26817498
51. Gebel HM, Scott JR, Parvin CA, Rodey GE. In vitro immunization to KLH. II. Limiting dilution analysis of
antigen-reactive cells in primary and secondary culture. J Immunol. 1983; 130(1):29–32. PMID:
6183352
52. van Schie KA, Wolbink GJ, Rispens T. Cross-reactive and pre-existing antibodies to therapeutic anti-
bodies—Effects on treatment and immunogenicity. MAbs. 2015; 7(4):662–71. PubMed Central PMCID:
PMCPMC4623040. https://doi.org/10.1080/19420862.2015.1048411 PMID: 25962087
53. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric
anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a
four-dose treatment program. J Clin Oncol. 1998; 16(8):2825–33. https://doi.org/10.1200/JCO.1998.16.
8.2825 PMID: 9704735
54. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, et al. Extended Rituximab
(anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodg-
kin’s lymphoma. Ann Oncol. 1999; 10(6):655–61. PMID: 10442187
55. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;
9(4):271–85. PubMed Central PMCID: PMCPMC2737409. https://doi.org/10.1038/nri2526 PMID:
19319144
56. de Andres C, Teijeiro R, Alonso B, Sanchez-Madrid F, Martinez ML, Guzman de Villoria J, et al. Long-
term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab ther-
apy in patients with multiple sclerosis. PLoS One. 2012; 7(4):e34103. PubMed Central PMCID:
PMCPMC3319565. https://doi.org/10.1371/journal.pone.0034103 PMID: 22496780
57. Baldwin HM, Ito-Ihara T, Isaacs JD, Hilkens CM. Tumour necrosis factor alpha blockade impairs den-
dritic cell survival and function in rheumatoid arthritis. Ann Rheum Dis. 2010; 69(6):1200–7. https://doi.
org/10.1136/ard.2009.110502 PMID: 19773288
58. Dahle´n R, Strid H, Lundgren A, Isaksson S, Raghavan S, Magnusson MK, et al. Infliximab Inhibits Acti-
vation and Effector Functions of Peripheral Blood T Cells in vitro from Patients with Clinically Active
Ulcerative Colitis. Scandinavian Journal of Immunology. 2013; 78(3):275–84. https://doi.org/10.1111/
sji.12081 PMID: 23713660
CD4+ T cell response to biopharmaceuticals
PLOS ONE | https://doi.org/10.1371/journal.pone.0178544 May 31, 2017 17 / 17
